<DOC>
	<DOCNO>NCT01290029</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability cinacalcet single oral dose child age 28 day less 6 year chronic kidney disease receive dialysis .</brief_summary>
	<brief_title>Study Evaluate Cinacalcet Children With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Subject 's parent , legally acceptable guardian , must sign Independent Ethics Committee ( IEC ) Institutional Review Board ( IRB ) approve Informed Consent Form . Subjects 28 day &lt; 6 year age chronic kidney disease ( CKD ) secondary hyperparathyroidism ( sHPT ) diagnose principal investigator , undergo hemodialysis peritoneal dialysis time screen ( subject 6 month old receive dialysis ≥ 1 month ) receive cinacalcet HCl therapy least 2 week prior dose Day 1 Free disease condition ( disease condition related renal disease , opinion investigator , would impact subject 's safety integrity study data ) . Must weigh ≥ 6 kg screen Day1 . Must least 30 week gestational age . Physical examination must acceptable investigator screen Day 1 . Hemoglobin ≥ 8 g/dL screen Day 1 . Serum calcium within ageappropriate normal range per National Kidney Foundation Kidney Disease Outcomes Quality Initiative ( NKF KDOQI ) guideline screen Day 1 Normal clinically acceptable electrocardiogram ( ECG ) ( 12lead reporting RR , PR , QRS , QTc interval ) screen Day 1 . Clinical laboratory test acceptable investigator screen Day 1 . Exclusion Criteria Current historic malignancy . Cardiac ventricular arrhythmia within 28 day prior screen . A gastrointestinal disorder surgery could affect absorption drug ( eg , pyloric stenosis gutshortening surgical procedure prior screen ) . A new onset seizure worsen preexisting seizure disorder within 2 month prior IP administration . Major surgery ( defined surgical procedure involve general anesthesia respiratory assistance ) within 28 day prior screen . Hepatic impairment indicate elevated level hepatic transaminase bilirubin ( aspartate aminotransferase ( AST ) ≥ 1.5 x upper limit normal ( ULN ) OR alanine aminotransferase ( ALT ) ≥ 1.5 x ULN OR total bilirubin ≥ 1 x ULN per institutional laboratory range ) screen Day1 . History prolongation QT interval ( eg , congenital long QT interval , second third degree heart block condition prolong QT interval ) Corrected QT Interval ( QTc ) &gt; 500 m screening , use Bazett 's formula QTc ≥ 450 ≤ 500 m screening , use Bazett 's formula , unless write permission enroll provide investigator consultation pediatric cardiologist Known hypersensitivity cinacalcet HCl excipients cinacalcet HCl . Use grapefruit juice , herbal medication potent CYP 3A4 inhibitor ( eg , erythromycin , clarithromycin , ketokonazole , itraconazole ) within 14 day prior enrollment study . Concurrent within 28 day prior enrollment use medication predominantly metabolize enzyme CYP2D6 narrow therapeutic index ( eg , flecainide , vinblastine , thioridazine , tricyclic antidepressant desipramine imipramine , betablockers metoprolol carvedilol ) . Concurrent within 28 day prior enrollment use medication prolong QT interval ( eg , sotalol , amiodarone , erythromycin , clarithromycin ) . Currently receive treatment another investigational device drug study , less 90 day since end treatment another investigational device drug study ( ) . Other investigational procedure participate study exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2190 Days</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pediatric</keyword>
	<keyword>CKD</keyword>
	<keyword>dialysis</keyword>
	<keyword>paediatric</keyword>
</DOC>